Market Insight: Glaucoma Surgery Is Moving Toward More Targeted, Procedure-Efficient Care

The global glaucoma surgery devices market is valued at USD 1.9 billion in 2026, with an estimated USD 1.97 billion in 2027 and a projected USD 2.91 billion by 2036, reflecting a 4.37% CAGR from 2027 to 2036. The underlying market opportunity is being shaped less by a single breakthrough technology and more by the convergence of minimally invasive procedures, laser-based treatment, improved intraocular pressure management, and growing demand for treatment approaches that reduce dependence on long-term pharmacological therapy.

A key shift is the increasing emphasis on procedure efficiency and patient convenience. Ophthalmic clinics are becoming an important growth channel as glaucoma treatment moves toward specialized outpatient environments. This favors devices that can support shorter, less invasive procedures while maintaining clinically meaningful intraocular pressure control.

Technology development is reinforcing this transition. Automated laser systems, minimally invasive glaucoma surgery platforms, and incision-free approaches are expanding the range of interventions available to ophthalmologists. The emergence of technologies such as Alcon's Voyager Direct Selective Laser Trabeculoplasty system illustrates how automation can potentially improve procedural consistency while reducing dependence on highly manual treatment workflows.

Regional Analysis: North America Leads While Asia Pacific Builds the Next Growth Engine

North America maintains a leading position in the glaucoma surgery devices market, supported by advanced ophthalmic infrastructure, established specialist networks, high procedure volumes, and relatively broad access to sophisticated glaucoma treatments. The region also provides an attractive environment for manufacturers introducing technologically advanced surgical and laser platforms because healthcare providers have greater familiarity with specialized ophthalmic interventions.

The competitive advantage of North America is therefore closely connected to technology readiness. Hospitals and ophthalmic centers can support sophisticated equipment, while established clinical ecosystems make it easier for manufacturers to introduce new treatment platforms and generate real-world clinical evidence.

Asia Pacific presents a different opportunity. The region is projected to grow at a 5.36% CAGR, making it the faster-growing regional market. Its expansion is associated with improving access to ophthalmic care, increasing hospital capacity, and broader availability of modern glaucoma procedures.

The strategic distinction between the two regions is important:

• North America: A mature market where innovation, clinical differentiation, automation, and premium technology adoption are key competitive factors.
• Asia Pacific: An expansion market where improving healthcare access and procedure availability can broaden the addressable patient base.

For device manufacturers, Asia Pacific can therefore provide a significant avenue for volume expansion, while North America remains important for technology commercialization and clinical adoption. Companies able to adapt product positioning to different healthcare infrastructure levels will be better positioned to capture both opportunities.

Industry Challenge: Clinical Adoption Must Overcome Cost, Workflow, and Evidence Barriers

Despite technological progress, adoption of glaucoma surgery devices is not automatic. One of the industry's central challenges is convincing physicians and healthcare providers that newer interventions offer sufficient advantages over established treatment pathways.

Glaucoma management often involves long-term pharmacological treatment, creating an entrenched clinical workflow. Surgical devices must therefore demonstrate more than technical novelty. Physicians need confidence that a new platform can deliver meaningful intraocular pressure control while fitting naturally into clinical practice.

Workflow integration is another important consideration. Advanced laser and surgical systems can require specialized training, equipment investment, and procedural expertise. This can make adoption more difficult in healthcare settings where ophthalmic resources are limited.

The challenge becomes particularly relevant when moving beyond highly developed markets. A device designed for sophisticated ophthalmic centers may face slower uptake in regions where access to trained specialists, capital equipment, or dedicated surgical infrastructure remains constrained.

Clinical evidence is also becoming an increasingly important commercial differentiator. Developments involving long-term real-world data, such as the evidence reported for Sight Sciences' OMNI Surgical System, show the industry's emphasis on demonstrating sustained clinical utility rather than relying solely on initial procedural results.

Consequently, manufacturers face a three-part adoption test:

1. Clinical value — Does the device deliver meaningful patient outcomes?
2. Operational value — Can physicians use it efficiently within existing workflows?
3. Economic value — Can healthcare providers justify adoption relative to existing treatment options?

Companies that address all three are more likely to convert technological innovation into sustained market penetration.

Product and Technology Comparison: Laser-Based Treatment Versus Minimally Invasive Surgery

Two important approaches shaping the glaucoma surgery devices landscape are laser-based treatment and minimally invasive glaucoma surgery (MIGS). Although both seek to improve intraocular pressure management, they address clinical workflows differently.

Laser-based approaches

Laser technologies can provide a less invasive treatment pathway and are increasingly benefiting from automation. The launch of Alcon's Voyager Direct Selective Laser Trabeculoplasty system highlights the industry's movement toward more automated glaucoma laser procedures.

Their key opportunity lies in procedure simplification and reduced invasiveness. Incision-free or laser-based interventions can be particularly attractive when clinicians seek alternatives to more invasive surgical procedures.

Minimally invasive surgical approaches

MIGS devices use surgical techniques designed to improve aqueous outflow while limiting the invasiveness associated with traditional glaucoma surgery. The OMNI Surgical System and other MIGS platforms demonstrate the industry's focus on combining pressure reduction with a comparatively streamlined surgical approach.

MIGS can be particularly relevant for patients who require more substantial intervention or for cases where clinicians seek to integrate glaucoma treatment with broader ophthalmic surgical management.

Strategic comparison

Factor	Laser-based treatment	Minimally invasive surgery
Primary attraction	Non-incisional or less invasive treatment	Targeted surgical intervention
Technology direction	Automation and procedural precision	Device-enabled surgical efficiency
Clinical opportunity	Earlier or less invasive intervention pathways	Patients requiring stronger procedural intervention
Competitive focus	Automation, usability and treatment consistency	Clinical outcomes, safety and durability

The two technologies should not necessarily be viewed as direct substitutes. Their coexistence reflects a broader market trend toward more personalized glaucoma treatment, where physicians can select interventions according to disease severity, patient needs, and procedural objectives.

Geographic Opportunity: Four Markets With Strategic Relevance

Beyond the broader regional picture, four geographic markets stand out for different strategic reasons.

United States: The United States remains a critical market for advanced glaucoma technology because of its established ophthalmic infrastructure and strong presence of leading device manufacturers. It is particularly relevant for companies seeking clinical adoption, product launches, and commercialization of sophisticated surgical and laser platforms.

Germany: Germany represents an important European opportunity given its position within an advanced healthcare ecosystem. The European commercialization of minimally invasive glaucoma technologies, including products receiving CE certification, can support broader regional adoption.

Israel: Israel is strategically relevant to the competitive landscape because companies such as Lumenis have established a presence in ophthalmic technology. The country's technology-oriented healthcare environment can support innovation and specialized ophthalmic applications.

China: China represents an important long-term opportunity within Asia Pacific as improving ophthalmic care access and expanding healthcare capacity create conditions for broader glaucoma procedure adoption. Its relevance is particularly strong for manufacturers looking beyond mature Western markets for future expansion.

Competitive Landscape: Companies Are Competing Through Technology, Evidence, and Portfolio Expansion

The competitive landscape includes established ophthalmic technology companies as well as specialized glaucoma device developers. Alcon, Glaukos, Carl Zeiss Meditec, Lumenis, Iridex, AbbVie, BVI Medical, and Ziemer Ophthalmic Systems are among the notable participants.

The direction of competition is increasingly visible in recent strategic and product developments.

Alcon has pursued both technology innovation and portfolio expansion. Its Voyager Direct Selective Laser Trabeculoplasty system emphasizes automation, while its acquisition of Belkin Vision expanded its glaucoma laser capabilities. Together, these moves suggest that leading companies see value in building broader glaucoma technology portfolios rather than relying on a single treatment modality.

Specialized companies are taking a different route by strengthening clinical differentiation. Sight Sciences' real-world evidence for the OMNI Surgical System demonstrates the importance of supporting device adoption with longer-term clinical data.

Smaller or specialized innovators are also contributing to the expansion of treatment options. ViaLase's CE Mark approval for its femtosecond laser-based system illustrates continued investment in incision-free glaucoma intervention, while New World Medical's expanded FDA clearance for the KDB GLIDE device broadens the potential clinical application of its platform.

Recent Industry News: 2024–2025 Developments Signal Faster Technology Commercialization

Recent industry developments show that glaucoma surgery technology is progressing across several fronts, from regulatory approvals and clinical evidence to acquisitions and automated treatment systems.

• August 2025 — Ciltech SAS: Ciltech SAS received CE certification under the EU Medical Device Regulation for its Intercil Uveal Spacer. The approval supports commercialization of the minimally invasive glaucoma implant across European markets and expands the availability of implant-based approaches for reducing intraocular pressure.
• February 2025 — Alcon: Alcon launched the Voyager Direct Selective Laser Trabeculoplasty system, positioned as a fully automated glaucoma laser. The development highlights the industry's movement toward greater procedural automation and technology-assisted treatment consistency.
• January 2025 — Sight Sciences: Sight Sciences released long-term real-world clinical data for its OMNI Surgical System. The reported evidence of sustained intraocular pressure control strengthens the role of clinical outcomes and real-world evidence in supporting wider adoption of MIGS technologies.
• July 2024 — Alcon: Alcon completed its acquisition of Belkin Vision, expanding its glaucoma laser portfolio. The transaction demonstrates the strategic importance of broadening technology capabilities as competition increasingly extends across multiple glaucoma treatment approaches.
• July 2024 — ViaLase: ViaLase received CE Mark approval for its femtosecond laser-based system for non-incisional trabeculotomy. The development reinforces interest in incision-free glaucoma procedures and expands the European technology landscape.
• May 2024 — New World Medical: New World Medical received FDA 510(k) clearance for expanded indications for its KDB GLIDE device, including standalone use for primary open-angle glaucoma. The regulatory development broadens the device's potential clinical application and supports further adoption of minimally invasive glaucoma procedures.

Read more about this report @ https://www.fundamentalbusinessinsights.com/industry-report/glaucoma-surgery-devices-market-14699

About

Fundamental Business Insights:

Fundamental Business Insights is global market research and consulting company which is engaged in providing in depth market reports to its various types of clients like industrial sectors, financial sectors, universities, non-profit, and corporations. Our goal is to offer the correct information to the right stakeholder at the right time, in a format that enables logical and informed decision making. We have a team of consultants who have experience in offering executive level blueprints of markets and solutions. Our services include syndicated market studies, customized research reports, and consultation.

Contact us:
Robbin Fernandez
Head of Business Development
Fundamental Business Insights and Consulting
Email:  sales@fundamentalbusinessinsights.com

Read This Report in Regional Languages - 

https://www.fundamentalbusinessinsights.com/ko/industry-report/glaucoma-surgery-devices-market-14699

https://www.fundamentalbusinessinsights.com/ja/industry-report/glaucoma-surgery-devices-market-14699

https://www.fundamentalbusinessinsights.com/de/industry-report/glaucoma-surgery-devices-market-14699

https://www.fundamentalbusinessinsights.com/it/industry-report/glaucoma-surgery-devices-market-14699

https://www.fundamentalbusinessinsights.com/es/industry-report/glaucoma-surgery-devices-market-14699

https://www.fundamentalbusinessinsights.com/fr/industry-report/glaucoma-surgery-devices-market-14699